异基因造血干细胞移植后急性移植物抗宿主病的治疗新靶点

doi:10.3969/j.issn.1006-5725.2025.05.003

Abstract

Abstract:

Allogeneic haematopoietic stem cell transplantation （allo-HSCT） is the most effective curative treatment for hematologic malignancies. Its efficacy hinges on eliminating primary hematological disorders and restoring bone marrow hematopoiesis during conditioning， as well as leveraging the graft-versus-leukemia （GVL） effect. However， acute graft-versus-host disease （aGVHD） remains a significant complication following allo-HSCT， substantially affecting patient survival and quality of life. Current preclinical studies focus on strategies to mitigate aGVHD while preserving adequate GVL effects to improve transplant outcomes. This review summarizes recent preclinical research findings in this field， emphasizing the regulatory roles and specific molecular mechanisms of T cells， antigen-presenting cells， myeloid-derived suppressor cells， and mesenchymal stem cells in aGVHD. It further highlights the latest therapeutic strategies for aGVHD from preclinical studies， aiming to provide valuable insights for researchers and clinicians to develop more effective therapeutic targets and strategies.

Key words: haematopoietic stem cell transplantation, acute graft-versus-host disease, graft-versus-leukemia effect, T cells, antigen-presenting cells, myeloid-derived suppressor cells, mesenchymal stem cells, signaling pathways

CLC Number:

R552

Haoliang DUAN,Yuhua RU,Jia. CHEN. New targets for the treatment of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation[J]. The Journal of Practical Medicine, 2025, 41(5): 634-640.

Figures/Tables 1

References 70

1	HILL G R， KOYAMA M. Cytokines and costimulation in acute graft-versus-host disease ［J］. Blood， 2020， 136（4）： 418-428. doi:10.1182/blood.2019000952 doi: 10.1182/blood.2019000952
2	JAMY O， ZEISER R， CHEN Y B. Novel developments in the prophylaxis and treatment of acute GVHD ［J］. Blood， 2023， 142（12）： 1037-1046. doi:10.1182/blood.2023020073 doi: 10.1182/blood.2023020073
3	张玉培，谢新生，石雅洁，等. 异基因造血干细胞移植治疗ASXL1基因突变的骨髓增生异常综合征患者的效果［J］. 实用医学杂志， 2023， 39（23）： 3087-3092. doi:10.3969/j.issn.1006-5725.2023.23.011 doi: 10.3969/j.issn.1006-5725.2023.23.011
4	PACZESNY S. Discovery and validation of graft-versus-host disease biomarkers ［J］. Blood， 2013， 121（4）： 585-594. doi:10.1182/blood-2012-08-355990 doi: 10.1182/blood-2012-08-355990
5	JIANG H， FU D， BIDGOLI A， et al. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor ［J］. Front Immunol， 2021， 12： 761448. doi:10.3389/fimmu.2021.761448 doi: 10.3389/fimmu.2021.761448
6	ZHAO K， RUAN S， YIN L， et al. Dynamic regulation of effector IFN-γ-producing and IL-17-producing T cell subsets in the development of acute graft-versus-host disease ［J］. Mol Med Rep， 2016， 13（2）： 1395-1403. doi:10.3892/mmr.2015.4638 doi: 10.3892/mmr.2015.4638
7	KARL F， HUDECEK M， BERBERICH-SIEBELT F， et al. T-Cell Metabolism in Graft Versus Host Disease ［J］. Front Immunol， 2021， 12： 760008. doi:10.3389/fimmu.2021.760008 doi: 10.3389/fimmu.2021.760008
8	CAMPE J， ULLRICH E. T Helper Cell Lineage-Defining Transcription Factors： Potent Targets for Specific GVHD Therapy？［J］. Front Immunol， 2021， 12： 806529. doi:10.3389/fimmu.2021.806529 doi: 10.3389/fimmu.2021.806529
9	CHOE H， FERRARA J L M. New therapeutic targets and biomarkers for acute graft-versus-host disease （GVHD）［J］. Expert Opin Ther Targets， 2021， 25（9）： 761-771. doi:10.1080/14728222.2021.1992383 doi: 10.1080/14728222.2021.1992383
10	FISCHER J C， BSCHEIDER M， GÖTTERT S， et al. Type I interferon signaling before hematopoietic stem cell transplantation lowers donor T cell activation via reduced allogenicity of recipient cells ［J］. Sci Rep， 2019， 9（1）： 14955. doi:10.1038/s41598-019-51431-2 doi: 10.1038/s41598-019-51431-2
11	THANGAVELU G， DU J， PAZ K G， et al. Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease ［J］. Blood， 2020， 135（1）： 28-40. doi:10.1182/blood.2019000032 doi: 10.1182/blood.2019000032
12	MIAO S， TANG B， LIU H， et al. CXCR3 blockade combined with cyclosporine A alleviates acute graft-versus-host disease by inhibiting alloreactive donor T cell responses in a murine model ［J］. Mol Immunol， 2018， 94： 82-90. doi:10.1016/j.molimm.2017.12.010 doi: 10.1016/j.molimm.2017.12.010
13	HUANG Y， ZOU Y， JIAO Y， et al. Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect ［J］. Front Immunol， 2022， 13： 751296. doi:10.3389/fimmu.2022.751296 doi: 10.3389/fimmu.2022.751296
14	LIU Y， WU Y， WANG Y， et al. IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects ［J］. Leukemia， 2015， 29（4）： 939-946. doi:10.1038/leu.2014.310 doi: 10.1038/leu.2014.310
15	SCHUTT S D， WU Y， KHAREL A， et al. The druggable transcription factor Fli-1 regulates T cell immunity and tolerance in graft-versus-host disease ［J］.J Clin Invest，2022，132（21）：e143950. doi:10.1172/jci143950 doi: 10.1172/jci143950
16	GAO Y， SHAN W， GU T， et al. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration ［J］. Front Immunol， 2021， 12： 785774. doi:10.3389/fimmu.2021.785774 doi: 10.3389/fimmu.2021.785774
17	WANG Q， SU X， HE Y， et al. CD11c participates in triggering acute graft-versus-host disease during bone marrow transplantation ［J］. Immunology， 2021， 164（1）： 148-160. doi:10.1111/imm.13350 doi: 10.1111/imm.13350
18	ZHU F， QIU T， ZHU S， et al. TIRC7 inhibits Th1 cells by upregulating the expression of CTLA‑4 and STAT3 in mice with acute graft‑versus‑host disease ［J］. Oncol Rep， 2020， 44（1）： 43-54.
19	YAO Y， WANG L， ZHOU J， et al. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect ［J］. J Transl Med， 2017， 15（1）： 28. doi:10.1186/s12967-017-1132-9 doi: 10.1186/s12967-017-1132-9
20	WU Y， BASTIAN D， SCHUTT S， et al. Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice ［J］. Biol Blood Marrow Transplant， 2015， 21（7）： 1195-1204. doi:10.1016/j.bbmt.2015.03.016 doi: 10.1016/j.bbmt.2015.03.016
21	IM K I， KIM N， LIM J Y， et al. The Free Radical Scavenger NecroX-7 Attenuates Acute Graft-versus-Host Disease via Reciprocal Regulation of Th1/Regulatory T Cells and Inhibition of HMGB1 Release ［J］. J Immunol， 2015， 194（11）： 5223-5232. doi:10.4049/jimmunol.1402609 doi: 10.4049/jimmunol.1402609
22	HE Y S， YANG X K， HU Y Q， et al. Emerging role of Fli1 in autoimmune diseases ［J］. Int Immunopharmacol， 2021， 90： 107127. doi:10.1016/j.intimp.2020.107127 doi: 10.1016/j.intimp.2020.107127
23	GONG H， MA S， CHEN J， et al. Dendritic cell-derived IL-27 p28 regulates T cell program in pathogenicity and alleviates acute graft-versus-host disease ［J］. Signal Transduct Target Ther， 2022， 7（1）： 319. doi:10.1038/s41392-022-01147-z doi: 10.1038/s41392-022-01147-z
24	LIU H， YU Z， TANG B， et al. LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease via Skewing Allogeneic T Cells Polarization Towards Treg Cells ［J］. Front Immunol， 2021， 12： 647894. doi:10.3389/fimmu.2021.762728 doi: 10.3389/fimmu.2021.762728
25	WU Y， TANG C-H A， MEALER C， et al. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function ［J］. Cell Mol Immunol， 2021， 18（3）： 632-643. doi:10.1038/s41423-020-00611-6 doi: 10.1038/s41423-020-00611-6
26	GAO Z， GAO Z， ZHANG H， et al. Targeting STING： From antiviral immunity to treat osteoporosis ［J］. Front Immunol， 2022， 13： 1095577. doi:10.3389/fimmu.2022.1095577 doi: 10.3389/fimmu.2022.1095577
27	MENDIRATTA M， MENDIRATTA M， GANGULY S， et al. Concurrent hypoxia and apoptosis imparts immune programming potential in mesenchymal stem cells： Lesson from acute graft-versus-host-disease model ［J］. Stem Cell Res Ther， 2024， 15（1）： 381. doi:10.1186/s13287-024-03947-2 doi: 10.1186/s13287-024-03947-2
28	MURRAY P J， ALLEN J E， BISWAS S K， et al. Macrophage activation and polarization： Nomenclature and experimental guidelines ［J］. Immunity， 2014， 41（1）： 14-20. doi:10.1016/j.immuni.2014.06.008 doi: 10.1016/j.immuni.2014.06.008
29	LIU X， SU Y， SUN X， et al. Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization ［J］. Sci China Life Sci， 2020， 63（11）： 1744-1754. doi:10.1007/s11427-019-1691-x doi: 10.1007/s11427-019-1691-x
30	SU Y， SUN X， LIU X， et al. hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype ［J］. J Hematol Oncol， 2022， 15（1）： 99. doi:10.1186/s13045-022-01323-2 doi: 10.1186/s13045-022-01323-2
31	KUBOTA N， SAITO A， TANAKA R， et al. Langerhans Cells Suppress CD8+ T Cells In Situ during Mucocutaneous Acute Graft-Versus-Host Disease ［J］. J Invest Dermatol， 2021， 141（5）：1177-1187.e3. doi:10.1016/j.jid.2020.09.018 doi: 10.1016/j.jid.2020.09.018
32	POBER J S， MEROLA J， LIU R， et al. Antigen Presentation by Vascular Cells ［J］. Front Immunol， 2017， 8： 1907. doi:10.3389/fimmu.2017.01907 doi: 10.3389/fimmu.2017.01907
33	WHEWAY J， OBEID S， COURAUD P O， et al. The brain microvascular endothelium supports T cell proliferation and has potential for alloantigen presentation ［J］. PloS One， 2013， 8（1）： e52586. doi:10.1371/journal.pone.0052586 doi: 10.1371/journal.pone.0052586
34	WANG W， YE Y， DU Y， et al. EPC infusion ameliorates acute graft-versus-host disease-related endothelial injury after allogeneic bone marrow transplantation ［J］. Front Immunol， 2022， 13： 1019657. doi:10.3389/fimmu.2022.1019657 doi: 10.3389/fimmu.2022.1019657
35	NAJI A， SUGANUMA N， ESPAGNOLLE N， et al. Rationale for Determining the Functional Potency of Mesenchymal Stem Cells in Preventing Regulated Cell Death for Therapeutic Use ［J］. Stem Cells Transl Med， 2017， 6（3）： 713-719. doi:10.5966/sctm.2016-0289 doi: 10.5966/sctm.2016-0289
36	TI D， HAO H， TONG C， et al. LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b ［J］. J Transl Med， 2015， 13： 308. doi:10.1186/s12967-015-0642-6 doi: 10.1186/s12967-015-0642-6
37	LEE J W， FANG X， KRASNODEMBSKAYA A， et al. Concise review： Mesenchymal stem cells for acute lung injury： role of paracrine soluble factors ［J］. Stem Cells， 2011， 29（6）： 913-919. doi:10.1002/stem.643 doi: 10.1002/stem.643
38	LI X， LIU L， YANG J， et al. Exosome Derived From Human Umbilical Cord Mesenchymal Stem Cell Mediates MiR-181c Attenuating Burn-induced Excessive Inflammation ［J］. EBioMedicine， 2016， 8： 72-82. doi:10.1016/j.ebiom.2016.04.030 doi: 10.1016/j.ebiom.2016.04.030
39	LIU W， ZHOU N， LIU Y， et al. Mesenchymal stem cell exosome-derived miR-223 alleviates acute graft-versus-host disease via reducing the migration of donor T cells ［J］. Stem Cell Res Ther， 2021， 12（1）： 153. doi:10.1186/s13287-021-02159-2 doi: 10.1186/s13287-021-02159-2
40	ZHOU L， LIU S， WANG Z， et al. Bone Marrow-Derived Mesenchymal Stem Cells Modified with Akt1 Ameliorates Acute Liver GVHD ［J］. Biol Proced Online， 2019， 21： 24. doi:10.1186/s12575-019-0112-2 doi: 10.1186/s12575-019-0112-2
41	HEGDE S， LEADER A M， MERAD M. MDSC： Markers， development， states， and unaddressed complexity ［J］. Immunity， 2021， 54（5）： 875-884. doi:10.1016/j.immuni.2021.04.004 doi: 10.1016/j.immuni.2021.04.004
42	TIAN X， WANG T， SHEN H， et al. Tumor microenvironment， histone modifications， and myeloid-derived suppressor cells ［J］. Cytokine Growth Factor Rev， 2023，74：108-121. doi:10.1016/j.cytogfr.2023.08.002 doi: 10.1016/j.cytogfr.2023.08.002
43	SPILLEBOUDT C， DE WILDE V， LEWALLE P， et al. Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease ［J］. Front Immunol， 2020， 11： 579151. doi:10.3389/fimmu.2020.579151 doi: 10.3389/fimmu.2020.579151
44	DE WILDE V， VAN ROMPAEY N， HILL M， et al. Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1 ［J］. Am J Transplant， 2009， 9（9）： 2034-2047. doi:10.1111/j.1600-6143.2009.02757.x doi: 10.1111/j.1600-6143.2009.02757.x
45	WANG K， LV M， CHANG Y J， et al. Early myeloid-derived suppressor cells （HLA-DR-/lowCD33+CD16-） expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease （GVHD） in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT ［J］. J Hematol Oncol， 2019， 12（1）： 31. doi:10.1186/s13045-019-0710-0 doi: 10.1186/s13045-019-0710-0
46	VILLARINO A V， KANNO Y， O'SHEA J J. Mechanisms and consequences of Jak-STAT signaling in the immune system ［J］.Nat Immunol， 2017， 18（4）： 374-384. doi:10.1038/ni.3691 doi: 10.1038/ni.3691
47	LIU Y， LIAO S， BENNETT S， et al. STAT3 and its targeting inhibitors in osteosarcoma ［J］. Cell Prolif， 2021， 54（2）： e12974. doi:10.1111/cpr.12974 doi: 10.1111/cpr.12974
48	KIM S Y， PARK M J， KWON J E， et al. Cucurbitacin E ameliorates acute graft-versus-host disease by modulating Th17 cell subsets and inhibiting STAT3 activation ［J］. Immunol Lett， 2018， 203： 62-69. doi:10.1016/j.imlet.2018.09.012 doi: 10.1016/j.imlet.2018.09.012
49	PERSAUD S P， RITCHEY J K， KIM S， et al. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation ［J］. J Clin Invest， 2021，131（24）：e145501. doi:10.1172/jci145501 doi: 10.1172/jci145501
50	张雨峤，梅伟健. 免疫检查点抑制剂治疗实体瘤的标志性成果［J］. 实用医学杂志， 2024， 40（2）： 272-277.
51	O'DONNELL J S， LONG G V， SCOLYER R A， et al. Resistance to PD1/PDL1 checkpoint inhibition ［J］. Cancer Treat Rev， 2017， 52： 71-81. doi:10.1016/j.ctrv.2016.11.007 doi: 10.1016/j.ctrv.2016.11.007
52	GENOVA C， DELLEPIANE C， CARREGA P， et al. Therapeutic Implications of Tumor Microenvironment in Lung Cancer： Focus on Immune Checkpoint Blockade ［J］. Front Immunol， 2021， 12： 799455. doi:10.3389/fimmu.2021.799455 doi: 10.3389/fimmu.2021.799455
53	ASAKURA S， HASHIMOTO D， TAKASHIMA S， et al. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice ［J］. J Clin Invest， 2010， 120（7）： 2370-2378. doi:10.1172/jci39165 doi: 10.1172/jci39165
54	NI X， SONG Q， CASSADY K， et al. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells ［J］. J Clin Invest， 2017， 127（5）： 1960-1977. doi:10.1172/jci91138 doi: 10.1172/jci91138
55	PAN B， SHANG L， LIU C， et al. PD-1 antibody and ruxolitinib enhances graft-versus-lymphoma effect without increasing acute graft-versus-host disease in mice ［J］. Am J Transplant， 2021， 21（2）： 503-514. doi:10.1111/ajt.16275 doi: 10.1111/ajt.16275
56	TSAI J J， VELARDI E， SHONO Y， et al. Nrf2 regulates CD4⁺ T cell-induced acute graft-versus-host disease in mice ［J］. Blood， 2018， 132（26）： 2763-2774. doi:10.1182/blood-2017-10-812941 doi: 10.1182/blood-2017-10-812941
57	YI T， LI X， WANG E， et al. Activation of the Nuclear Erythroid 2-Related Factor 2 Antioxidant Responsive Element （Nrf2-ARE） Signaling Pathway Alleviates Acute Graft-Versus-Host Disease by Reducing Oxidative Stress and Inhibiting Infiltration of Inflammatory Cells in an Allogeneic Stem Cell Transplantation Mouse Model ［J］. Med Sci Monit， 2018， 24： 5973-5979. doi:10.12659/msm.908130 doi: 10.12659/msm.908130
58	YANG Y， LI J， LEI W， et al. CXCL12-CXCR4/CXCR7 Axis in Cancer： from Mechanisms to Clinical Applications ［J］. Int J Biol Sci， 2023， 19（11）： 3341-3359. doi:10.7150/ijbs.82317 doi: 10.7150/ijbs.82317
59	WU N， LIU R， LIANG S， et al. γδ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation ［J］. Front Immunol， 2021， 12： 687961. doi:10.3389/fimmu.2021.687961 doi: 10.3389/fimmu.2021.687961
60	王瑞娟，李超，段丽娟，等. 氯普噻吨调节Akt/mTOR通路对人急性髓系白血病细胞自噬和凋亡的影响［J］. 实用医学杂志， 2023， 39（20）： 2584-2590.
61	MEHTA M， GOHIL D， KHATTRY N， et al. Prevention of acute graft-versus-host-disease by Withaferin a via suppression of AKT/mTOR pathway ［J］. Int Immunopharmacol， 2020， 84： 106575. doi:10.1016/j.intimp.2020.106575 doi: 10.1016/j.intimp.2020.106575
62	XIANG H， ZHU F， XU Z， et al. Role of Inflammasomes in Kidney Diseases via Both Canonical and Non-canonical Pathways ［J］. Front Cell Dev Biol， 2020， 8： 106. doi:10.3389/fcell.2020.00106 doi: 10.3389/fcell.2020.00106
63	ZHAO Y， HUANG J， LI T， et al. Berberine ameliorates aGVHD by gut microbiota remodelling， TLR4 signalling suppression and colonic barrier repairment for NLRP3 inflammasome inhibition ［J］. J Cell Mol Med， 2022， 26（4）： 1060-1070. doi:10.1111/jcmm.17158 doi: 10.1111/jcmm.17158
64	KUMAR GUPTA S， GOHIL D， DUTTA D， et al. Withaferin-A alleviates acute graft versus host disease without compromising graft versus leukemia effect ［J］. Int Immunopharmacol， 2023， 121： 110437. doi:10.1016/j.intimp.2023.110437 doi: 10.1016/j.intimp.2023.110437
65	CHEN W， SU G， XU Y， et al. Caspase-1 inhibition ameliorates murine acute graft versus host disease by modulating the Th1/Th17/Treg balance ［J］. Int Immunopharmacol， 2021， 94： 107503. doi:10.1016/j.intimp.2021.107503 doi: 10.1016/j.intimp.2021.107503
66	BASTIAN D， WU Y， BETTS B C， et al. The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease ［J］. Front Immunol， 2019， 10： 988. doi:10.3389/fimmu.2019.00988 doi: 10.3389/fimmu.2019.00988
67	SONG Q， WANG X， WU X， et al. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity ［J］. Blood， 2021， 137（16）： 2243-2255. doi:10.1182/blood.2020006345 doi: 10.1182/blood.2020006345
68	GONG H， MA S， LIU S， et al. IL-17C Mitigates Murine Acute Graft-vs.-Host Disease by Promoting Intestinal Barrier Functions and Treg Differentiation ［J］. Front Immunol， 2018， 9： 2724. doi:10.3389/fimmu.2018.02724 doi: 10.3389/fimmu.2018.02724
69	LI X， ZHANG C， CHEN W， et al. Protective effect of neutralizing anti-IL-18α monoclonal antibody on a mouse model of acute graft-versus-host disease ［J］. Oncol Rep， 2015， 34（4）： 2031-2039. doi:10.3892/or.2015.4176 doi: 10.3892/or.2015.4176
70	XING S， ZHANG X， LIU J H， et al. Host MyD88 signaling protects against acute graft-versus-host disease after allogeneic bone marrow transplantation ［J］. Clin Exp Immunol， 2019， 195（1）： 121-131. doi:10.1111/cei.13215 doi: 10.1111/cei.13215

[1]	Haiyang LU,Weili ZHAO,Xiaoxia. HU. Gut microbiota modulates immune reconstitution in allogeneic hematopoietic stem cell transplantation [J]. The Journal of Practical Medicine, 2025, 41(5): 628-633.
[2]	Zonglin LI,Chunlin FENG,Xin LIU,Xingming SHU,Min. SONG. CCCTC⁃binding factors promote the formation of oxaliplatin related gastric cancer drug-tolerant cells by resisting apoptosis [J]. The Journal of Practical Medicine, 2025, 41(4): 490-499.
[3]	Huiling CAO,Jie ZHANG,Xiaofei ZHU,Shining QIAN,Yunfeng. CHEN. Study on the mechanism of tetramethylpyrazine pretreatment umbilical cord mesenchymal stem cell transplantation in the treatment of ischemic stroke [J]. The Journal of Practical Medicine, 2025, 41(2): 178-185.
[4]	Qing LUO,Jinjin HUANG,Tingting REN,Ruihua ZHOU,Donghua XU,Zhenhua WANG,Guoying WANG. The effect of umbilical cord stem cell exosomes on the proliferation of dermal papilla cells [J]. The Journal of Practical Medicine, 2024, 40(20): 2828-2834.
[5]	Zhaochen SUN,Junyan JIANG,Yitian. CHEN. Advancements in CAR⁃T cell research for the treatment of colorectal cancer [J]. The Journal of Practical Medicine, 2024, 40(18): 2640-2646.
[6]	Jiao XU,Min ZHANG,Guogang. XIE. Research progress of mast cell⁃derived exosomes in bronchial asthma [J]. The Journal of Practical Medicine, 2024, 40(15): 2194-2198.
[7]	Zijuan FU,Qian LI,Lin LU,Yongqiu. LI. Relationship of serum ANGPTL3 and NFATc1 levels with the severity and prognosis in cerebral infarction patients [J]. The Journal of Practical Medicine, 2024, 40(10): 1407-1411.
[8]	DONG Jiayi, SHAO Lijuan, ZHENG Zhu, CHEN Size.. Research progress of CAR⁃T combined molecule⁃targeted drugs in the treatment of solid tumors [J]. The Journal of Practical Medicine, 2023, 39(7): 798-803.
[9]	CHEN Xia, WU Xinxin, LIU Xingyou, CHEN Xinhao, HUANG Yinxia, XIAO Zhiyuan, HE Jigang. . Overexpressed NKx2.5 genes in mesenchymal stem cells improve myocardial function in patients with myo⁃ cardial infarction via enhancing SDF⁃1/CXCR4⁃axis homing [J]. The Journal of Practical Medicine, 2023, 39(6): 660-666.
[10]	CHEN Fukun, LV Juan, DENG Zhiyong. Effect of chimeric antigen receptor gene⁃modified T⁃cell immunotherapy for lung cancer：A systematic review [J]. The Journal of Practical Medicine, 2023, 39(5): 538-543.
[11]	HOU Yongzhe, ZHANG Qin, ZHAO Xiaochen, HE Miao, YU Lingling, BAI Hai, WU Tao.. Research progress of extracellular vesicles derived from mesenchymal stem cells in treatment of acute lung injury [J]. The Journal of Practical Medicine, 2023, 39(3): 390-394.
[12]	Ruiting XI,Suxia GENG,Xin HUANG,Minming LI,Chengxin DENG,Yulian WANG,Lisi HUANG,Jianyu WENG,Xin. DU. Levels and significance of γδ T cells and their subpopulations in the bone marrow of MDS patients [J]. The Journal of Practical Medicine, 2023, 39(24): 3195-3199.
[13]	Dan XIE,Shi. OUYANG. Effect of Yinchenhao Decoction combined with exosomes derived from umbilical cord mesenchymal stem cells on acute liver failure and hepatocyte pyroptosis [J]. The Journal of Practical Medicine, 2023, 39(23): 3034-3042.
[14]	Shuwen JIN,Wei LIU,Jiabao LIU,Jianchao FAN,Yongli HAN,Li ZHOU,Paidi XU,Hongxing. ZHANG. Mechanism of electroacupuncture for gastric hypersensitivity in functional dyspepsia rats rats through NGF/TrKA/TRPV1 pathway [J]. The Journal of Practical Medicine, 2023, 39(22): 2928-2933.
[15]	Mengyi ZHANG,Yangyang YU,Zhengya LI,Yongzhen YU,Chunli ZHANG,Tianhao CHENG,Yixiao LEI,Wenjie ZHOU,Xiulan ZOU,Yuping ZOU. Correlation of Tfh cell content in peripheral blood proportion and intracellular IL⁃21 with retinal damage caused by blue light [J]. The Journal of Practical Medicine, 2023, 39(21): 2743-2749.

New targets for the treatment of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 70

Related Articles 15

Recommended Articles

Metrics

Comments